<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndromes</z:hpo> (MDSs) are clonal hematopoietic stem cell (<z:chebi fb="15" ids="50443">HSC</z:chebi>) <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> that are characterized by ineffective hematopoiesis and frequent progression to <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Thus far, few treatments can actually alter the natural history of this disease </plain></SENT>
<SENT sid="2" pm="."><plain>Allogeneic stem-cell transplantation for high-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> is becoming the only curative therapy probably because of the improvement of bone marrow transplant procedures </plain></SENT>
<SENT sid="3" pm="."><plain>The lack of other options underscores the urgent need to develop new therapy </plain></SENT>
<SENT sid="4" pm="."><plain>The prevailing model suggests that genetic and/or epigenetic alterations that occur in <z:chebi fb="15" ids="50443">HSCs</z:chebi> or <z:chebi fb="15" ids="50443">HSC</z:chebi> niche compromise <z:chebi fb="15" ids="50443">HSC</z:chebi> function, resulting in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>; therefore, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> <z:chebi fb="15" ids="50443">HSCs</z:chebi> are likely the ideal targets for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> treatment </plain></SENT>
<SENT sid="5" pm="."><plain>Recent encouraging advances-capturing a molecular portrait of the whole genome of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> CD34(+) cells, including identifying altered signaling pathways and altered microRNAs-have improved our understanding of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> pathogenesis and provided novel potential clinical targets for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Here, I will briefly review the characteristics of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> <z:chebi fb="15" ids="50443">HSCs</z:chebi> and discuss the therapeutic promise of targeting <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> <z:chebi fb="15" ids="50443">HSCs</z:chebi> </plain></SENT>
</text></document>